Key Findings:  This study was conducted to assess changes in the quality of life in patients with symptoms of autism spectrum disorder (ASD) who use cannabis-based medicinal products (CBMPs) for efficacy and safety. Results showed an overall safe and tolerable profile, and participants had improvement in quality of life, as well as anxiety and sleep symptoms following CBMP treatment. Also reported was a reduction in concomitant prescribing of benzodiazepines and neuroleptics.
Type of Study:  Meta-analysis
Study Sample Size:  74
Study Result:  Positive
Study Location(s):  United Kingdom
Year of Pub:  2022
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Cannabinoid (unspecified)
Phytocannabinoid Source:  Unspecified
Receptors Studied:  CB1
Ligands Studied:  GABA, Serotonin
Dosage: Median dose: CBD 10.0mg/day Δ 9 -THC 112.5mg/day
Route of Administration:  Inhalation, Oral (Ingestion), Sublingual/Oromucosal